PSYCHOSOMATICS

Clinical Approach to Personality Change Due to Another Medical Condition
Leppla I, Fishman D, Kalra I and Oldham MA
Medical personality change (MPC) is a codable diagnosis (i.e., F07.0) that deserves consideration when a patient is inexplicably no longer "acting like him/herself." Its presentation ranges from subtle to severe and is often characterized by bafflingly poor judgment and impairment in several aspects of a person's life. Despite the global impact that MPC can have on a patient's functioning, occupation, and relationships, this condition receives far less clinical consideration than better known syndromes such as depression or anxiety and is often likely incorrectly formulated as such.
Clonazepam for Catatonia Incompletely Responsive to lorazepam
Jiang S, Brownell KC, Kamper JE and Stewart JT
Diabetic Retinopathy and Depression: A Risk Assessment
Kawada T
WITHDRAWN: Psychosis: A Presentation of COVID-19?
Lim LJH, Ghosh AK and Tammy Tsang YY
This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.
Optimizing Fit: Targeting a Residency Psychiatry Consultation-Liaison Rotation to Various Levels of Training
Beach SR, Shalev D, Fischel SV, Boland RJ and Ernst CL
Determining the optimal timing and structure for a core residency rotation in consultation-liaison psychiatry (CLP) remains a key challenge for program directors and rotation leaders. Previous surveys have been conducted regarding these questions, and guidelines from national organizations have been issued, but practices remain varied among institutions.
Medical Complications of Anorexia Nervosa
Cass K, McGuire C, Bjork I, Sobotka N, Walsh K and Mehler PS
The purpose of this study was to describe the medical complications of anorexia nervosa (AN) to enable a consult-liaison psychiatrist to be familiar with these complications when involved with the care of a hospitalized patient with AN.
Capacity and the COVID-19 Surge
Rasimas JJ
Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae
Hamm BS and Rosenthal LJ
Chloroquine and hydroxychloroquine are among several experimental treatments being investigated in the urgent response to the coronavirus disease-2019. With increased use of these medications, physicians need to become knowledgeable of these drugs' neuropsychiatric side effects and interactions with psychiatric medications.
Psychological Influence of Coronovirus Disease 2019 (COVID-19) Pandemic on the General Public, Medical Workers, and Patients With Mental Disorders and its Countermeasures
Wang S, Wen X, Dong Y, Liu B and Cui M
Coronovirus disease 2019 (COVID-19) first broke out in Wuhan, Hubei Province, China, in 2019, and now it spreads in more than 100 countries around the world. On January 30th, the World Health Organization (WHO) declared COVID-19 a public health emergency of international concern. It was classified as a pandemic by the WHO on March 11, 2020. With the increase in the number of cases reported by various countries every day, the COVID-19 pandemic has attracted more and more attention around the world. At the same time, this public health emergency has caused a variety of psychological problems, such as panic disorder, anxiety, and depression. In addition, the Wuhan Mental Health Center's analysis of 2144 calls from the psychological hotline from February 4 to February 20, 2020, showed that the general public accounted for 70%, medical workers accounted for 2.2%, patients with mental disorders accounted for 19.5%, and other personnel accounted for 8.3% (https://mp.weixin.qq.com/s/kmff1vnaLsT2d9xQkK5pwg).
Trikafta and Psychopathology in Cystic Fibrosis: A Case Report
Tindell W, Su A, Oros SM, Rayapati AO and Rakesh G
Clonidine and Tizanidine for Management of Bipolar Disorder Due to Dengue Encephalopathy: A Case Report
Pariwatcharakul P and Srifuengfung M
The Incapacitated Surrogate: What is the Consultation-Liaison Psychiatrist's Role?
Allen N and Mishkin A
When a patient is found to be lacking capacity to make a medical decision, the medical team is advised to turn to the patient's most appropriate surrogate decision maker (hereafter, surrogate) to make a choice on behalf of the patient. The assumption made by the medical team is that the surrogate will have the capacity to make appropriate medical decisions on behalf of the patient. At times though, the capacity of the surrogate himself may be called into question, leading to uncertainty in terms of how best to proceed in the care of the patient. Consultation-liaison psychiatrists are commonly consulted to assess a patient's capacity to make a particular medical decision, but their role assisting in cases of incapacitated surrogates is less clear.
Coronavirus and Its Implications for Psychiatry: A Rapid Review of the Early Literature
Cabrera MA, Karamsetty L and Simpson SA
The coronavirus pandemic has changed health care rapidly and dramatically.
Dermatitis Neglecta, the Cognitive Assessment, and Micronutrients
Brown TM
Addiction Management in Hospitalized Patients With Intravenous Drug Use-Associated Infective Endocarditis
Ray V, Waite MR, Spexarth FC, Korman S, Berget S, Kodali S, Kress D, Guenther N and Murthy VS
Infections related to intravenous drug use and opioid use disorders (OUDs) are increasing nationwide. Endocarditis is a recognized complication of intravenous drug use, and inpatient treatment typically focuses on infection management without attention to underlying addiction.
Vaping Cannabis Oil: A Case of Catatonia Associated With Use of High-Potency Cannabis
Manning T, Bartow C, McNaughton M, Reynolds E and Chen Z
Physical Health and Psychosocial Considerations During the Coronavirus Disease 2019 Outbreak
Giacalone A, Rocco G and Ruberti E
Intravenous Misuse of Unsterilized Methamphetamine Bong Water Laced With Vape Juice
Constant JS and Fleisch SB
Neurocovid: Pharmacological Recommendations for Delirium Associated With COVID-19
Baller EB, Hogan CS, Fusunyan MA, Ivkovic A, Luccarelli JW, Madva E, Nisavic M, Praschan N, Quijije NV, Beach SR and Smith FA
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as one of the biggest health threats of our generation. A significant portion of patients are presenting with delirium and neuropsychiatric sequelae of the disease. Unique examination findings and responses to treatment have been identified.
Applying (or Not?) CAR-T Neurotoxicity Experience to COVID-19 Delirium and Agitation
Mack AH and Schofield HL
Design and Implementation of a Regional Inpatient Psychiatry Unit for Patients who are Positive for Asymptomatic SARS-CoV-2
Angelino AF, Lyketsos CG, Ahmed MS, Potash JB and Cullen BA
Patients with psychiatric illnesses are particularly vulnerable to highly contagious, droplet-spread organisms such as SARS-CoV-2. Patients with mental illnesses may not be able to consistently follow up behavioral prescriptions to avoid contagion, and they are frequently found in settings with close contact and inadequate infection control, such as group homes, homeless shelters, residential rehabilitation centers, and correctional facilities. Furthermore, inpatient psychiatry settings are generally designed as communal spaces, with heavy emphasis on group and milieu therapies. As such, inpatient psychiatry services are vulnerable to rampant spread of contagion.